Kodiak Sciences, Inc. (KOD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$35.36-2.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KOD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KOD — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended June 30, 2026 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for…
Why it matters: Keeping cash is important for Kodiak's work. Updates will show financial health.
Worry ifAn announcement will confirm cash runway goes past 2027.
Less concerning ifA report will show cash runway is shorter than expected or needs quick action.
Why it matters: Results from the PEAK study will indicate KSI-101's effectiveness in treating macular edema. This is key for Kodiak's growth.
Supportive ifThe PEAK study shows good results in treating macular edema.
Worry ifTopline data shows KSI-101 does not meet its primary endpoint.
Why it matters: Topline results will show how well Zenkuda and KSI-501 work in treating wet AMD. This is crucial for Kodiak's future.
Supportive ifThe DAYBREAK study shows that visual acuity gains are not worse than expected.
Worry ifTopline data shows Zenkuda and KSI-501 do not meet the primary endpoint.
Why it matters: This data will show how well Zenkuda works in treating wet AMD. Positive results could boost confidence in Kodiak's pipeline.
Supportive ifTopline data shows Zenkuda meets the primary endpoint in the DAYBREAK study.
Worry ifTopline data shows Zenkuda fails to meet the primary endpoint in the DAYBREAK study.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$294 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $719 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,624 loss on $10,000 · 36.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash runway will indicate if Kodiak can fund its operations through 2027.
Worry ifThey announced that their cash will last well into 2027.
Less concerning ifThey announced concerns about cash or the need for more funding.
Why it matters: Updates on cash position will show if Kodiak can fund its operations into 2027. This is crucial for its ongoing studies.
Worry ifKodiak reports cash and cash equivalents above $169.5 million.
Less concerning ifKodiak reports cash and cash equivalents below $150 million.
Why it matters: Keeping cash reserves is important. It helps fund clinical trials and operations until 2027.
Worry ifCash and cash equivalents reported to be above $150 million.
Less concerning ifCash and cash equivalents are below $150 million.
Why it matters: Updates on Phase 3 assets will show if Kodiak is moving forward with key products. This is crucial for future growth.
Supportive ifA press release confirming advancement of at least one Phase 3 asset.
Worry ifNo updates or delays in the advancement of Phase 3 assets.
Why it matters: Enrollment progress indicates the demand for KSI-501 and its potential market impact. Delays could signal issues.
Supportive ifEnrollment in the ALTO study reaches or exceeds the target of 910 patients.
Worry ifEnrollment in the ALTO study is below the target. This shows possible challenges ahead.
Why it matters: A successful BLA submission for Zenkuda would help Kodiak grow and improve its market presence.
Supportive ifKodiak announces the BLA submission for Zenkuda is on track and expected soon.
Worry ifDelays or issues arise in the BLA submission process for Zenkuda.
Why it matters: Updates on KSI-501 will show how well it treats eye swelling and its market position.
Watch forUpdates show KSI-501 works better than aflibercept in the ALTO study.
Also watch forUpdates show KSI-501 does not work better than aflibercept.
Why it matters: Topline results in September 2026 will show if Zenkuda and KSI-501 are effective for wet AMD. This could impact future regulatory approval.
Supportive ifThe data shows Zenkuda and KSI-501 have similar gains in vision.
Worry ifTopline data shows neither drug meets the primary endpoint.
Why it matters: Results in December 2026 will show how well KSI-101 works for macular edema. This could change its market potential.
Supportive ifTopline data shows KSI-101 meets its primary endpoint in the PEAK study.
Worry ifTopline data shows KSI-101 fails to meet its primary endpoint.
Why it matters: Cash levels are critical for funding ongoing clinical trials. A decline could signal financial stress.
Worry ifCash and cash equivalents are over $100 million. This supports operations into 2027.
Less concerning ifCash and cash equivalents fall below $100 million. This raises worries about funding.